CurrentKaiser PermanentePolicy N/A

Clinical Review Criteria Neutron Beam Radiotherapy

Defines Kaiser Permanente Clinical Review Criteria for the medical necessity of neutron beam radiotherapy for specific tumor types (soft tissue sarcoma, salivary gland tumors, locally advanced prostate cancer) and states investigational status for other indications; includes documentation and applicable billing codes guidance.

Policy Summary

PayerKaiser Permanente

PolicyClinical Review Criteria Neutron Beam Radiotherapy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionRequesting provider must send the last 6 months of clinical notes from the requesting provider and/or specialist to support medical necessity when requesting neutron beam radiotherapy.

POLICY UPDATE CHANGES

No material clinical or coverage changes in this update per brief (has_material_change=false).

3Primary covered tumor types listed

10+Indications considered investigational

1Applicable HCPCS code listed

Coverage Summary

Overview: This policy covers Neutron Beam Radiotherapy (subject: Neutron Beam Radiotherapy), with a mixed coverage stance. Status: CURRENT. Last review: 2025-04-01. Primary tumor types considered for coverage under Kaiser Permanente Clinical Review Criteria are: soft tissue sarcoma, salivary gland tumors, and locally advanced prostate cancer. Other indications are considered investigational (not medically necessary).

Medical Necessity Criteria

Medicare Members

In absence of CMS coverage guidance, Kaiser Permanente applies Non-Medicare criteria for medical necessity determinations.

ALL of the following

No applicable CMS guidance: No applicable CMS Coverage Manuals, NCD, LCD, or Local Coverage Article; Kaiser Permanente uses its own Clinical Review Criteria, Neutron Beam Radiotherapy, for medical necessity determinations for Medicare members.
Refer to Non-Medicare criteria: Refer to the Non-Medicare criteria below for specific indications and requirements.

Non-Medicare Members - Medically Necessary Indications

Covered when ANY of the following tumor-specific conditions are met:

Tumor-specific indications

Soft tissue sarcoma with inoperable tumor.
Salivary gland tumors that are inoperable; or locally advanced tumor especially in persons with gross residual disease; or unresectable tumor.
Locally advanced prostate cancer.

Non-Medicare Members - Experimental/Investigational (Not Medically Necessary)

Neutron beam therapy is considered experimental and investigational for all other indications including, but not limited to, the following:

Investigational indications

Colon cancer.
Glioma.
Dermatofibrosarcoma protuberans.
Kidney cancer.
Lung cancer.

Documentation Requirements to Support Medical Necessity

When requesting neutron beam radiotherapy, submit the following:

Documentation requirement: Last 6 months of clinical notes from requesting provider and/or specialist.

Provider Actions

Documentation Required

Submit clinical documentation

Requesting provider must send the last 6 months of clinical notes from the requesting provider and/or specialist to support medical necessity when requesting neutron beam radiotherapy.

Last 6 months of clinical notes from requesting provider and/or specialist

Prior Authorization

Verify authorization requirements

Use the Pre-authorization Code Check to confirm whether an authorization is required by the patient’s plan for the specific service code before scheduling or billing.

77423

Denial Risk

Claims may be denied if indication is investigational

Neutron beam therapy requests for indications listed in the policy as experimental or investigational are considered not medically necessary and may be denied.

Refer to the policy’s Experimental/Investigational list in the criteria section for specific indications

Background and Evidence

Background: Neutron radiotherapy is a high linear-energy-transfer (high-LET) radiation modality with greater biological effectiveness than conventional photon radiotherapy; it typically requires a lower total tumor dose and fewer treatments. Historically used since 1938 and redeveloped in the 1960s–1970s, modern neutron facilities are limited in number in the U.S. and available at only a few centers.

Evidence summary and policy interpretation: The overall evidence base is limited and inconsistent. For salivary gland tumors evidence (one small RCT plus case series) is suggestive of benefit for locoregional control but not conclusive. For soft tissue sarcoma evidence consists mainly of case series without randomized trials and is inadequate to determine efficacy. For locally advanced prostate cancer two RCTs produced mixed results with methodological limitations. At the policy level, findings are suggestive for salivary gland tumors but inconclusive, and results are mixed or insufficient for other indications.

Indication	Evidence summary
Soft tissue sarcoma	Case series only; no RCTs identified; efficacy cannot be determined from descriptive reports (largest studies n=73 and n=161); does not meet MTAC.
Salivary gland tumors	One small randomized trial (n=32 randomized, n=25 analyzed) showing improved locoregional control versus photons; additional case series (including a UW series n=128); suggestive but not conclusive evidence; does not meet MTAC.
Locally advanced prostate cancer	Two RCTs with mixed results (some improvement in locoregional control, inconsistent survival findings), methodological limitations and potential selection bias; evidence does not meet MTAC.

Definitions: MTAC — Medical Technology Assessment Criteria used by Kaiser Permanente to evaluate technologies and inform whether a technology meets criteria for medical use; referenced in policy determinations regarding neutron beam radiotherapy.

Revision History

10/06/2020updated

Removed unrelated SRS and SBRT LCD from Medicare, deferred to Kaiser Permanente criteria for Medicare.

12/05/2017adopted

Adopted clinical criteria for Neutron Beam Therapy.

05/26/2015added

Added CPT codes.

09/08/2015revised

Revised LCD L34151.